We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Marja-Riitta Taskinen

Marja-Riitta Taskinen MD

Professor of Medicine, Helsinki University Hospital, Helsinki, Finland

Marja-Riitta Taskinen is an Emerita Professor of Medicine and her team is a member of the Research Program Unit, Diabetes & Obesity Research program at the University of Helsinki. Currently she leads her research team at Biomedicum Helsinki focusing on lipoprotein kinetics in health and metabolic disorders including diabetes and dyslipidemias and genetics of familial dyslipidemias. 

Professor Taskinen has over 400 original publications and over 100 reviews and chapters (H-index 83). Her outstanding achievements have been recognized by several international awards including the Claude Bernard Award (EASD 2002), Edwin Bierman Award (ADA 2004) and Novartis Award (2006). She has been involved in activities of European Atherosclerosis Society (President of EAS 2006-2008) and IAS (International Atherosclerosis Society) as well as of the EASD and IDF (International Diabetes Federation). Professor Taskinen was a member of the task force on “ESC guidelines on diabetes, pre-diabetes and cardiovascular diseases” developed in collaboration with the EASD in 2013. She also continues as a member of the EAS/ESC Guidelines committee on Management of dyslipidemias and member of EAS Consensus Paper Panel. Her group is currently a partner in a EU-project RESOLVE (FP7-HEALTH-2012-INNOVATION-1), which started in 2013. Professor Taskinen is also a member of NIH (1R01HL113315-01) funded consortium “Genomic and Metabolomic Profiling of Finnish Familial Dyslipidemia Families” that started in 2012.


I have the following potentially relevant conflict(s) of interest to report:

Receipt of grants/research supports: Amgen, Merck, Sharpe & Dohme, Novo Nordisk

Sanofi Aventis

Receipt of honoraria or consultation fees: Amgen, Astra Zeneca, Chiesi Pharma, Pfizer, Sanofi


Participation in a company sponsored speaker’s


Amgen, Novo Nordisk